- Case report
- Open Access
Chronic myeloid leukemia with an e1a3 BCR-ABL fusion protein: transformation to lymphoid blast crisis
- Jordi Martinez-Serra†1, 6Email author,
- Raquel del Campo†2,
- Antonio Gutierrez†1, 6,
- Jose Luis Antich3,
- Magdalena Ginard3,
- Maria A Durán1,
- Leyre Bento1, 6,
- Teresa Ros1,
- Juan C Amat1,
- Carmen Vidal4,
- Julio F Iglesias5,
- Izabela Orlinska1 and
- Joan Besalduch1, 6
© Martinez-Serra et al.; licensee BioMed Central Ltd. 2014
Received: 27 June 2014
Accepted: 29 July 2014
Published: 14 August 2014
Chronic myelogenous leukemia (CML) results from the neoplastic transformation of a hematopoietic stem cell. CML is cytogenetically characterized by the presence of the Philadelphia chromosome (Ph’). Most patients with CML express e13a2 or e14a2 mRNAs that result from a rearrangement of the major breakpoint cluster regions (M-BCR) generating the 210-kDa (p210BCR-ABL) fusion proteins b2a2 or b3a2 respectively. The e1a3 CML-related atypical translocation has been reported with an indolent clinical course, low leukocyte count, long chronic phase even without treatment and good response to therapy. We report the case of a patient initially diagnosed as CML in chronic phase whose cells expressed the e1a3 variant. The patient readily responded to imatinib 400 mg with the achievement of a rapid complete cytogenetic response and the normalization of the blood count values, but after 5 months transformed into lymphoid blast crisis.
Chronic myelogenous leukemia (CML) results from the neoplastic transformation of a hematopoietic stem cell. This leukemia is cytogenetically characterized by the presence of the Philadelphia chromosome (Ph’), which results from the reciprocal translocation t(9;22) (q34;q11) that juxtaposes the c-abl oncogene 1 (ABL1) gene on chromosome 9 with the breakpoint cluster region (BCR) gene on chromosome 22 generating the BCR-ABL1 oncogene [1–3]. The BCR-ABL fusion protein is the product of the Philadelphia chromosome . Depending on the location of the breakpoint in BCR, several types of BCR-ABL fusion protein may be formed . To date 3 main breakpoint cluster regions in the BCR gene have been reported: The M-bcr region located between exons 12 and 16, the m-bcr located between exons e2′ and e2 and the u-bcr located in exon 19 [5–7]. The point of rupture in the ABL gene usually occurs in exon 2 (a2). Most patients with CML express e13a2 or e14a2 mRNAs that result from a rearrangement of the major breakpoint cluster regions (M-BCR) generating the 210-kDa (p210BCR-ABL) fusion proteins b2a2 or b3a2 respectively, mainly associated to CML. Another typical breakpoint within the BCR occurs in exons 1 (e1) and 19 (e19) generating the rearrangements e1a2 (p190BCR-ABL) or e19a2 (p230BCR-ABL), associated to acute lymphoblastic leukemia (ALL) or neutrophil CML, respectively [5–8]. The type of rearrangement in CML is thought to be related to the patient clinical course. Here we report a CML case with the rare e1a3 translocation. One of the main features of this type of translocation is the absence of the exon a2, normally present in the other translocations. The e1a3 BCR-ABL1 related CML has been reported with an indolent clinical course, low leukocyte count, long chronic phase even without treatment and good response to therapy [9, 10]. The abl exon a2 sequence, code for a part of the SH3 region of the abl protein, involved in the negative regulation of the kinase domain. Bcr-Abl mutants with deleted SH3 induce growth-factor independence and transform murine bone marrow, but leukemic cell proliferation in vivo is delayed as a result of reduced tissue invasiveness or leukemogenesis [9, 11, 12]. We report the case of a patient initially diagnosed as CML in chronic phase whose cells expressed the e1a3 variant. This patient readily responded to imatinib 400 mg with the achievement of a rapid complete cytogenetic response and the normalization of the blood count values, but after 5 months transformed into lymphoid blast crisis.
The rare e1a3 translocation has already been reported in the literature in 3 patients with CML in chronic phase and in 10 patients with ALL [9, 10, 13–17]. Surprisingly, most previously reported cases were detected in ALL patients and only in a few patients with CML in chronic phase. This fact together with the benign or indolent course of the CML with low leukocyte counts could lead to an underdiagnosed malignancy . Moreover, the difficulties in detecting this atypical translocation with platforms such as GeneXpert could enhance the diagnostic problems of this type of translocation . We hypothesize that these e1a3 ALL could represent lymphoid blast crisis of underdiagnosed e1a3 CML. To our knowledge there are no myeloid blast crisis described with the e1a3 rearrangement. Deletion of the exon a2 (ABL) from the BCR-ABL fusion transcript results in a protein that lacks the N-terminal two thirds of the Src homology 3 (SH3) domain [9, 16]. Several authors have already indicated that the SH3 domain of the chimeric tyrosine kinase is not necessary for the activation of intracellular signals regulating proliferation and survival (RAS, PI-3K, JNK, MAPK, STATs and c-MYC) of hematopoietic cells but it is essential for full leukemogenic potential in vivo [11, 12]. In this context, and based on a few cases, the presence of this translocation has been associated with good outcome of the disease for CML ; there is no such evidence for ALL. However due to the reduced number of e1a3 CML cases, it is necessary to accumulate more clinical evidences in order to clarify the relationship between the presence of the e1a3 BCR-ABL translocation and their clinical course that could be similar or worse than standard p210 CML as it could confer a higher risk of transformation to ALL.
This report describes the first case of a CML in chronic phase with an e1a3 translocation (with a suggested indolent course), which after 5 months in complete cytogenetic remission transformed into a lymphoid blast crisis. This case suggests that although imatinib therapy is able of inducing a very favorable response in the patient does not exempt them from undergoing to blast crisis. On the other hand, we provide a rationale to consider that e1a3 CML may have a tendency to progress to a lymphoid blast crisis, sometimes with the chronic phase underdiagnosed.
Written informed consent was obtained from the patient’s next of kin for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Prieto F, Egozcue J, Forteza G, Marco F: Identification of the Philadelphia (Ph-1) Chromosome. Blood 1970,35(1):23–27.PubMedGoogle Scholar
- Rowley JD: Molecular analysis of rearrangements in Philadelphia (Ph1) chromosome-positive leukemia. Haematol Blood Transfus 1989, 32: 3–10.PubMedGoogle Scholar
- Rowley JD: Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973,243(5405):290–293. 10.1038/243290a0PubMedView ArticleGoogle Scholar
- Nowell PC, Hungerford DA: Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960, 25: 85–109.PubMedGoogle Scholar
- Deininger MW, Goldman JM, Melo JV: The molecular biology of chronic myeloid leukemia. Blood 2000,96(10):3343–3356.PubMedGoogle Scholar
- Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G: Structural organization of the bcr gene and its role in the Ph’ translocation. Nature 1985,315(6022):758–761. 10.1038/315758a0PubMedView ArticleGoogle Scholar
- Laurent E, Talpaz M, Kantarjian H, Kurzrock R: The BCR gene and philadelphia chromosome-positive leukemogenesis. Cancer Res 2001,61(6):2343–2355.PubMedGoogle Scholar
- Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R, Meloni G, Saglio G, Salvatore F, Rotoli B: Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 1996,88(7):2410–2414.PubMedGoogle Scholar
- Al-Ali HK, Leiblein S, Kovacs I, Hennig E, Niederwieser D, Deininger M: CML with an e1a3 BCR-ABL fusion: rare, benign, and a potential diagnostic pitfall. Blood 2002,100(3):1092–1093. 10.1182/blood-2002-03-0930PubMedView ArticleGoogle Scholar
- Roman J, Jimenez A, Barrios M, Castillejo JA, Maldonado J, Torres A: E1A3 as a unique, naturally occurring BCR-ABL transcript in an indolent case of chronic myeloid leukaemia. Br J Haematol 2001,114(3):635–637. 10.1046/j.1365-2141.2001.02971.xPubMedView ArticleGoogle Scholar
- Nieborowska-Skorska M, Wasik MA, Slupianek A, Salomoni P, Kitamura T, Calabretta B, Skorski T: Signal transducer and activator of transcription (STAT) 5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med 1999,189(8):1229–1242. 10.1084/jem.189.8.1229PubMed CentralPubMedView ArticleGoogle Scholar
- Skorski T, Nieborowska-Skorska M, Wlodarski P, Wasik M, Trotta R, Kanakaraj P, Salomoni P, Antonyak M, Martinez R, Majewski M, Wong A, Perussia B, Calabretta B: The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion, and homing. Blood 1998,91(2):406–418.PubMedGoogle Scholar
- Pallisgaard N, Hokland P, Riishoj DC, Pedersen B, Jorgensen P: Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia. Blood 1998,92(2):574–588.PubMedGoogle Scholar
- Chen Y, Wang HW, Chen XH, Xu ZF, Qin YH, Ren FG, Li GX, Liang D, Liu DD: [Adult acute lymphoblastic leukemia with atypical BCR-ABL transcript e1a3: a case report and literature review]. Zhonghua Xue Ye Xue Za Zhi 2013,34(11):965–966.PubMedGoogle Scholar
- Fujisawa S, Nakamura S, Naito K, Kobayashi M, Ohnishi K: A variant transcript, e1a3, of the minor BCR-ABL fusion gene in acute lymphoblastic leukemia: case report and review of the literature. Int J Hematol 2008,87(2):184–188. 10.1007/s12185-008-0031-5PubMedView ArticleGoogle Scholar
- Langabeer SE, Haslam K, Kelly J, Leahy M, Vandenberghe E: Acute lymphoblastic leukaemia with an e1a3 BCR-ABL1 fusion. Acta Haematol 2011,126(4):214–215. 10.1159/000330956PubMedView ArticleGoogle Scholar
- Burmeister T, Schwartz S, Taubald A, Jost E, Lipp T, Schneller F, Diedrich H, Thomssen H, Mey UJ, Eucker J, Rieder H, Gokbuget N, Hoelzer D, Thiel E: Atypical BCR-ABL mRNA transcripts in adult acute lymphoblastic leukemia. Haematologica 2007,92(12):1699–1702. 10.3324/haematol.11737PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.